Lee Douglas was a co-founder of COR Therapeutics, Inc. During his 10 years at COR, he served in a number of senior management positions, including COR's original CEO. Since 1998, Mr. Douglas has been an independent consultant to biotechnology companies, including Cytokinetics, Inc and Sunesis Pharmaceuticals, Inc. He was a member of the founding teams of FivePrime and Portola Pharmaceuticals, Inc., where he continues to serve as an advisor. Mr. Douglas also serves as a member of the board of Affymax, Inc. and Aerovance, Inc. Prior to co-founding COR, he was a general partner in the venture group at Robertson, Stephens & Co, and was involved in the start-up of several companies including Protein Design Labs, Inc. Mr. Douglas is also a Visiting Scholar in the Molecular and Cell Biology Department at University of California at Berkeley, where he conducts independent research on cytoskeletal motor proteins as drug targets in the protozoal parasites Trypanosoma brucei and Leishmania. He received his M.B.A. from Harvard Business School, MCRP from the Harvard Graduate School of Design and B.A. from University of North Carolina at Charlotte. If his research project makes sufficient progress, he hopes to enter a formal Ph.D. program before he gets too old to complete it.
